Essenvia

AI-powered RIM platform automating FDA submissions for MedTech

Website: https://essenvia.com/

Cover Block

Attribute Details
Company Name Essenvia
Tagline AI-powered RIM platform automating FDA submissions for MedTech
Headquarters Los Angeles, United States
Founded 2018
Stage Series A
Business Model SaaS
Industry Healthtech
Technology AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label Series A (total disclosed ~$5,480,000)

Links

Summary and Signal

Essenvia is an early-stage startup automating the complex, manual process of FDA submissions for medical device companies [Founder Institute, pre-2023]. Founded in 2018, the Los Angeles-based company has built a SaaS platform that uses AI to structure regulatory workflows and generate key documentation for formats like the 510(k) and eSTAR [Founder Institute, pre-2023]. The founding team pairs Soumya Mahapatra, whose background includes management roles in manufacturing, with Basant Sahoo, a data science professional [LinkedIn, 2026], [The Org, 2026].

To date, Essenvia has raised approximately $5.5 million across two rounds, including a $4 million Pre-Series A led by Benhamou Global Ventures and Wavemaker360 in mid-2023 [Benhamou Global Ventures, 2023], [Tracxn, 2025]. Its business model targets subscription revenue from MedTech firms, positioning itself against established quality management system (QMS) vendors by focusing specifically on the submission automation layer. The primary question for the next 12-18 months is whether the company can transition from promoting performance claims, such as a 40% reduction in submission time, to publicly disclosing named enterprise customers and third-party-validated deployment case studies [Founder Institute, pre-2023].

Data Accuracy: YELLOW -- Key funding and team details are corroborated by multiple databases, but product performance claims and revenue metrics are sourced primarily from the company.

Taxonomy Snapshot

Axis Classification
Stage Series A
Business Model SaaS
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding ~$5.5M (estimated)

Company Overview

Essenvia was founded in 2018 by Soumya Mahapatra and Basant Sahoo in Los Angeles, California [Crunchbase]. The company operates as a SaaS provider in the healthtech sector, focusing on regulatory information management (RIM) for medical device manufacturers [Tracxn, 2025]. Its founding thesis centers on applying automation and AI to the traditionally manual, error-prone process of preparing and submitting documentation to the U.S. Food and Drug Administration.

Public milestones include participation in the Founder Institute accelerator program [Founder Institute, pre-2023]. A key funding event occurred in May 2023, when Essenvia raised a $4 million Pre-Series A round led by Benhamou Global Ventures and Wavemaker360 [Benhamou Global Ventures, 2023], [Pulse2, 2023]. This capital injection was followed by an undisclosed round later that year [Tracxn, 2025], bringing total disclosed funding to approximately $5.48 million.

The company's current stage is labeled as Series A, with a team size estimated at fewer than 25 employees [ZoomInfo]. Public records do not yet show named customer deployments or significant partnership announcements beyond the initial investor group, which also includes Rebright Partners, Pasadena Angels, and First Rays [Tracxn, 2025].

Data Accuracy: YELLOW -- Basic founding and funding facts are corroborated by multiple databases, but team and traction details are limited to single-source estimates.

The Product and the Stack

Essenvia's public positioning centers on a software platform designed to automate and manage the regulatory process for medical device companies. The core promise is to accelerate market access by streamlining the preparation and submission of documents to the U.S. Food and Drug Administration, specifically targeting the 510(k) and eSTAR pathways. The company claims its AI-powered system centralizes regulatory workflows, provides intelligence tools, and connects users with specialists [Founder Institute, pre-2023].

Available sources detail several specific product claims, though all originate from the company or its early-stage backers. The platform is said to reduce submission preparation time by 40% and eliminate 52% of errors [Founder Institute, pre-2023]. A more recent claim on its website guarantees a 100% acceptance rate for eSTAR submissions prepared using its "patented platform" [Essenvia, 2026]. The product appears to be offered as a SaaS solution, though pricing and specific module details are not publicly available.

Data Accuracy: YELLOW -- Product claims are sourced from company materials and an accelerator profile; performance metrics lack third-party validation.

Market Research and Opportunity

The market for regulatory software in medical technology is being reshaped by a global push for faster device approvals and a concurrent shift toward more complex, digital-first regulatory processes.

The broader quality management software (QMS) market for life sciences, which includes regulatory compliance functions, was valued at approximately $1.8 billion in 2023 and is projected to grow at a compound annual rate of 11% [Grand View Research, 2023]. This growth is driven by the expanding global medical device market, which itself is expected to reach $800 billion by 2030 [Precedence Research, 2023]. The addressable segment for software automating FDA-specific submissions like 510(k) and eSTAR is a subset of this larger QMS and regulatory affairs software spend.

Demand for specialized solutions is anchored in several persistent industry pain points. The regulatory burden for medical device companies is intensifying, with the FDA receiving over 3,000 510(k) submissions annually [FDA, 2023]. Manual preparation for these submissions is notoriously time-consuming and error-prone, creating a direct operational cost and a delay to market that can impact revenue by millions. The agency's mandated transition to the electronic Submission Template And Resource (eSTAR) format for most 510(k)s, completed in late 2023, created a specific, time-bound catalyst. This shift forced a technological upgrade for many companies, opening a window for new software vendors that could natively support the structured digital format.

Metric Value
Global Medical Device Market (2030 projection) $800B
Life Sciences QMS Software Market (2023) $1.8B
FDA 510(k) Submissions (Annual) 3,000 submissions

Data Accuracy: YELLOW -- Market sizing figures are from analogous, third-party industry reports, not specific to the AI-RIM niche. The FDA submission volume is a confirmed public statistic.

The Competitive Field

Essenvia's core bet is that a specialized AI layer can automate the most tedious and error-prone parts of the regulatory submission process, a niche where established quality management platforms have been slow to innovate.

Company Positioning Stage / Funding Notable Differentiator
Essenvia AI-powered RIM platform focused on automating FDA submissions (e.g., eSTAR, 510(k)). Series A; $5.48M total funding (estimated) Claims to guarantee 100% eSTAR acceptance rate via a patented platform
Greenlight Guru Dedicated QMS (Quality Management System) for medical device companies. Venture-backed; acquired by AssurX in 2022 Comprehensive, purpose-built QMS with strong brand recognition
Qualio Cloud-based QMS for life sciences, emphasizing ease of use and speed. Venture-backed; $80M total funding (estimated) Modern, intuitive interface targeting smaller, fast-growing firms
Arena QMS PLM (Product Lifecycle Management) with integrated QMS capabilities. Part of PTC; established enterprise vendor. Deep integration between product design and quality processes
MasterControl Enterprise quality and manufacturing execution software. Privately held; mature, large-scale vendor. Dominant incumbent with extensive validation libraries

Data Accuracy: YELLOW -- Competitor profiles and funding stages are drawn from Crunchbase and company sources, but Essenvia's differentiation claims are sourced solely from its own marketing materials.

Opportunity

If Essenvia can establish its AI-driven platform as the default operating system for medical device regulatory submissions, it stands to capture a significant portion of a multi-billion dollar market for compliance software and services.

The headline opportunity is to become the category-defining regulatory information management (RIM) platform for small to mid-sized medical device companies. This outcome is reachable because the company's product directly targets a critical, high-friction, and mandatory bottleneck for its customers: FDA approval. Unlike generic quality management systems, Essenvia's platform is built specifically for automating the creation and submission of complex FDA documents like eSTAR and 510(k) applications [Founder Institute, pre-2023].

Data Accuracy: YELLOW -- Scenario catalysts and market context are based on public regulatory trends and competitive positioning. Specific growth catalysts (e.g., partnership deals) are not yet publicly confirmed for Essenvia.

Sources

Articles about Essenvia

Related companies

Topics

View on Startuply.vc